Cargando…
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, we sought to investigate the preclinical activity of the MDM2 antagonist, Nutlin-3a, in Philadelphia positive (Ph(+)) and negative (Ph(−)) leukemic cell line models, and primary B-acute lymphoblastic leukemia (ALL) patie...
Autores principales: | Trino, Stefania, Iacobucci, Ilaria, Erriquez, Daniela, Laurenzana, Ilaria, De Luca, Luciana, Ferrari, Anna, Luserna Di Rorà, Andrea Ghelli, Papayannidis, Cristina, Derenzini, Enrico, Simonetti, Giorgia, Lonetti, Annalisa, Venturi, Claudia, Cattina, Federica, Ottaviani, Emanuela, Abbenante, Maria Chiara, Russo, Domenico, Perini, Giovanni, Musto, Pellegrino, Martinelli, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914334/ https://www.ncbi.nlm.nih.gov/pubmed/26887044 http://dx.doi.org/10.18632/oncotarget.7339 |
Ejemplares similares
-
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021) -
P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia
por: Trino, Stefania, et al.
Publicado: (2016) -
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016) -
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2015) -
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2020)